SANTA CLARA, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Applied Imaging
Corp. (Nasdaq: AICX) today announced the formation of a clinical research
imaging collaboration with The University of Texas M. D. Anderson Cancer
Center. As one part of this collaboration, the Division of Pathology and
Laboratory Medicine at M. D. Anderson has purchased the Company's Ariol(TM)
and SPOT(TM) automated image analysis systems for use in a number of the
cancer center's clinical research laboratories. Researchers at M. D. Anderson
will utilize these systems in ongoing research programs to more precisely
characterize gene and protein expression patterns in a wide range of cancers.
M. D. Anderson also will be evaluating new applications under development by
Applied Imaging and will provide input into the design and performance
characteristics of these new applications.
According to Stanley Hamilton, MD, professor and head of the Division of
Pathology and Laboratory Medicine at M.D. Anderson, "We have chosen to expand
our long-standing relationship with Applied Imaging because of the increasing
importance of the accurate measurement of gene and protein expression levels
to each of our clinical research programs. Many new cancer therapeutics
currently being developed will require sophisticated and precise diagnostic
test results in order to select those patients who are most likely to benefit
from these precisely targeted therapeutics. The Ariol and SPOT systems
developed by Applied Imaging have the capability to substantially accelerate
our research efforts in these areas. In addition, we look forward to
participating in the development and testing of a number of new microscopic
imaging applications being developed by the Company."
Carl Hull, Chief Executive Officer of Applied Imaging, commented, "We are
honored to have been selected by M. D. Anderson as their partner in this
collaboration, given the cancer center's extensive experience with the full
range of imaging technologies that are commercially available today. We
believe that the results of our ongoing collaboration with one of the world's
leading cancer treatment centers will lead to new and improved applications
for our Ariol and SPOT systems."
About M. D. Anderson Cancer Center
The University of Texas M. D. Anderson Cancer Center is one of the world's
most respected medical centers devoted exclusively to cancer patient care,
research, education and prevention. M. D. Anderson is one of the nation's
original three Comprehensive Cancer Centers designated by the National Cancer
Act of 1971 and is one of 39 such centers today. This year, about 60,000
people with cancer will receive care at M. D. Anderson. More than 11,000
patients will participate in clinical research exploring novel therapies and
diagnostic tests in 2003, the largest such program in the nation.
M. D. Anderson ranks among the nation's top two cancer hospitals according
to U.S. News & World Report's "America's Best Hospitals" survey. The Division
of Pathology and Laboratory Medicine occupies over 120,000 square feet in six
adjoining buildings within the M. D. Anderson complex in the Texas Medical
Center in Houston. The Division employs 75 clinical and research doctoral
faculty and 25 clinical fellows. The clinical laboratory processes over four
million tests per year.
About Applied Imaging
Applied Imaging Corp., based in Santa Clara, California, is the leading
supplier of automated imaging systems utilized in genetics and pathology
laboratories throughout the world for the analysis of chromosomes in cancer
and prenatal disorders. The Company markets a range of imaging systems for
fluorescence and brightfield microscopy applications, including the Company's
Ariol(TM), MDS(TM), SPOT(TM), CytoVision(R), PowerGene(R) and QUIPS(R) product
lines. Applied Imaging has installed in excess of 3,000 systems in over 1,000
laboratories in more than 60 countries. Applied Imaging provides clinical and
research applications. A research application is not intended for in vitro
diagnostic or clinical use.
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, regarding, among other
matters, the timing and successful introduction of new and improved
microscopic imaging applications, as well as the duration and benefits of the
collaboration with M. D. Anderson. Forward looking statements address matters
that are subject to a number of risks, uncertainties and other factors,
detailed in the Company's periodic filings with the Securities and Exchange
Commission including, but not limited to, those risks and uncertainties listed
in the section entitled "Management's Discussion and Analysis of Financial
Condition and Results of Operations - Factors Affecting Future Results," in
Applied Imaging's annual report on Form 10-K for the year ended December 31,
2002. The forward-looking statements are made as of October 29, 2003, and
Applied Imaging is under no obligation to revise or update the forward-looking
statements.
For additional information on Applied Imaging, visit the Company's Web
site at http://www.aicorp.com.
SOURCE Applied Imaging Corp.
 back to top
Related links:
http://www.aicorp.com
CONTACT:
Barry Hotchkies, CFO of Applied Imaging
Corp., +1-408-562-0250; or Jocelyn Hunter of FRB/Weber Shandwick,
+1-415-248-3433, for Applied Imaging Corp.
|
